JNJ-26990990
id:
jnj-26990990-320-16800841
title:
JNJ-26990990
text:
JNJ-26990990 is a broad-spectrum anticonvulsant drug currently under development by Janssen Pharmaceutica as a second-generation follow-up to the marketed drug topiramate. It was designed to have the same anticonvulsant effects as topiramate, but without the side effects associated with topiramate's carbonic anhydrase inhibition. It also has potential use in the treatment of inflammatory pain, neuropathic pain, and depression. JNJ-26990990 entered phase II clinical trials in October 2007. Metabo
brand slug:
wiki
category slug:
encyclopedia
description:
Experimental anticonvulsant drug
original url:
https://en.wikipedia.org/wiki/JNJ-26990990
date created:
date modified:
2023-12-20T19:45:05Z
main entity:
{"identifier":"Q15409418","url":"https://www.wikidata.org/entity/Q15409418"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/f/fa/JNJ-26990990.svg","width":620,"height":376}
fields total:
13
integrity:
15